MOLN

Molecular Partners AG (MOLN) is a dynamic clinical-stage biopharmaceutical company headquartered in Schlieren, Switzerland, dedicated to developing cutting-edge protein-based therapeutics for oncology and viral infections. Utilizing its proprietary Darpin and Drug Conjugate technology platforms, the company focuses on creating targeted therapies that improve efficacy and reduce side effects, aiming to address critical unmet medical needs. With a robust clinical pipeline and a commitment to innovation, Molecular Partners is strategically positioned to make significant contributions to the biopharmaceutical industry and enhance patient outcomes.